Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

References ↵ Lopez Pineiro M, Willis E, Yao C, et al . Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. SAGE Open Med Case Rep 2018; 6: ...

JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...

Send comments and news tips to [email protected]. Cite this: Edited by Deepa Varma. Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed - Medscape - July 11, 2025.

InflaRx has taken the difficult decision to abandon its drug development programme, vilobelimab, for rare inflammatory skin disorder pyoderma gangrenosum (PG), a move that has pummelled its share ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board.